Loading...
01/10 17:27
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The company reported strong financial performance with a significant increase in revenue and profitability, alongside optimistic guidance. The Q&A highlighted high demand and potential growth in OCD and MDD treatments. While there are risks like regulatory scrutiny and supply chain challenges, the positive market response to new product developments and stable gross margins contribute to a favorable outlook. Despite the lack of a shareholder return plan, the overall sentiment is positive due to the promising market potential and financial health.
Revenue (Q4 2024) $11.4 million, a 27% increase from $9 million in Q4 2023.
Revenue (Full Year 2024) $41 million, a 29% increase from $31.8 million in 2023.
Gross Profit (Q4 2024) $8.5 million, maintaining a gross margin of 75%, compared to $6.7 million in Q4 2023.
Gross Profit (Full Year 2024) $30.6 million, maintaining a gross margin of 75%, compared to $23.5 million in 2023.
Operating Profit (Q4 2024) Approximately $430,000, compared to approximately $180,000 in Q4 2023.
Operating Profit (Full Year 2024) Approximately $1.4 million, compared to an operating loss of $5 million in 2023.
Adjusted EBITDA (Q4 2024) $1.4 million, compared to approximately $750,000 in Q4 2023.
Adjusted EBITDA (Full Year 2024) $4.5 million, compared to an adjusted EBITDA loss of $2.4 million in 2023.
Net Income (Q4 2024) $1.5 million, compared to $127,000 in Q4 2023.
Net Income (Full Year 2024) Approximately $2.9 million, compared to a net loss of $4.2 million in 2023.
Cash Position (End of 2024) $69.4 million, including $20 million from equity financing.
Deep TMS System Sales: In Q4 2024, BrainsWay shipped 75 Deep TMS systems, a 25% increase compared to the same period last year.
OCD Treatment: The Deep TMS system is the first TMS therapy approved for obsessive compulsive disorder, with a potential market of approximately 400,000 patients annually.
Elderly MDD Treatment: The FDA raised the upper age limit for MDD treatment with Deep TMS from 68 to 86 years, making it the first TMS device approved for elderly patients.
Adolescent Depression Research: BrainsWay is collecting data on Deep TMS for potential treatment of adolescent depression.
PTSD Reimbursement: Approval for reimbursement of Deep TMS therapy for PTSD in Israeli public hospitals has been granted.
Market Expansion: BrainsWay has expanded its market presence, optimizing its sales force to target larger institutional and enterprise accounts in the US and internationally.
Global Reach: The company has established a global reach across key markets including Canada, Asia, India, and Europe.
Gross Margin: The gross margin for Q4 2024 was 75%, consistent with the previous year.
Net Income: BrainsWay reported positive net income for the fifth consecutive quarter.
Cash Position: As of December 31, 2024, BrainsWay had $69.4 million in cash, including $20 million from equity financing.
Revenue Guidance for 2025: BrainsWay anticipates revenue between $49 million to $51 million for 2025, representing a growth of 20% to 24% over 2024.
R&D Focus: The company aims to advance its next-generation Deep TMS 360 system and conduct clinical trials to enhance treatment capabilities.
Market Conditions: Shifting market conditions resulting from geopolitical, supply chain and other factors may impact business operations.
Regulatory Issues: The company is subject to regulatory scrutiny, particularly regarding the approval and reimbursement of its TMS therapy in various markets.
Supply Chain Challenges: Potential disruptions in the supply chain could affect the availability and distribution of Deep TMS systems.
Competitive Pressures: The company faces competition in the TMS market, which may impact its market share and pricing strategies.
Economic Factors: Economic downturns or changes in healthcare funding could affect customer purchasing decisions and overall demand for TMS therapy.
Sales Growth: Generated $11.4 million in revenue for Q4 2024, a 27% year-over-year increase.
Market Expansion: Expanded market presence in Canada, Asia, India, and Europe.
Product Development: Advancing next-generation Deep TMS 360 system and conducting clinical trials.
Customer Partnerships: Multi-year agreements with large enterprise networks to strengthen customer partnerships.
Recurring Revenue Model: Lease-based business model expanding recurring revenue base.
Clinical Trials: Conducting trials to enhance treatment capabilities for various conditions.
2025 Revenue Guidance: Expected revenue range of $49 million to $51 million, representing 20% to 24% growth over 2024.
Operating Income Guidance: Anticipated operating income of 3% to 4% for full year 2025.
Adjusted EBITDA Guidance: Expected adjusted EBITDA of 11% to 12% for full year 2025.
Market Potential for OCD: Targeting a market of approximately 400,000 patients annually for OCD treatment.
Market Potential for Depression: Addressing a large medical need affecting 10 million to 60 million adults in the US.
Shareholder Return Plan: None
Equity Financing: $20 million in gross proceeds received from equity financing with Valor Equity Partners.
Net Income: Net income of approximately $2.9 million for full year 2024.
Cash Position: Cash, cash equivalents, and short-term deposits of $69.4 million as of December 31, 2024.
The company demonstrates strong financial performance with increased revenue, gross profit, and net profit. The positive cash flow and substantial cash reserves further enhance financial stability. The raised revenue guidance and promising market expansion initiatives are optimistic. The Q&A section reveals potential growth through accelerated protocols and minority investments, despite some management ambiguity. Overall, the company's strategic investments and market expansion efforts indicate a positive outlook, likely resulting in a stock price increase within the 2% to 8% range.
The earnings call presented strong financial performance with a 26% revenue increase, robust gross profit margins, and a significant net profit rise. The Q&A section highlighted positive developments like potential FDA clearance, strategic financing, and successful collaborations. Despite increased expenses, efficient cost management and strong cash position support financial health. The reiterated revenue guidance and strategic expansions further bolster a positive outlook. Given these factors, the stock price is likely to experience a positive movement in the short term.
The earnings call reflects strong financial performance with a 27% revenue increase and significant growth in Deep TMS system shipments. The company is expanding internationally and maintaining robust margins. Despite geopolitical risks and supply chain concerns, management remains optimistic, supported by positive clinical data and market expansion strategies. The lack of a share repurchase program is a minor negative, but overall, the guidance and financial health suggest a positive market reaction over the next two weeks.
The company reported strong financial performance with a significant increase in revenue and profitability, alongside optimistic guidance. The Q&A highlighted high demand and potential growth in OCD and MDD treatments. While there are risks like regulatory scrutiny and supply chain challenges, the positive market response to new product developments and stable gross margins contribute to a favorable outlook. Despite the lack of a shareholder return plan, the overall sentiment is positive due to the promising market potential and financial health.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
